Tag: focus

HOUSTON, July 24, 2025 (GLOBE NEWSWIRE) -- Archrock, Inc. (NYSE: AROC) (“Archrock” or the “Company”) today announced that its Board of Directors has declared an increased quarterly dividend of $0.21 per share of common stock, or $0.84 per share on an annualized basis. The second quarter 2025 dividend will be paid on August 12, 2025 to all stockholders of record on August 5, 2025.

_{⁽¹⁾ Volume is measured on a standard physical case basis and is used to standardize differing package configurations delivered via direct store delivery.}

VERO BEACH, Fla., July 24, 2025 (GLOBE NEWSWIRE) --  (July 24, 2025) – Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced results of operations for the three month period ended June 30, 2025.

The In-Studio and Online Event Featured Over 10,000 Bordeaux-centric Bottles From the Collection of Malik M. Hasan, M.D.

PLANTATION, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Dr. Joel Berley, a nationally respected oral surgeon and founder of Plantation Oral Surgery, is pleased to announce the official launch of the 2026 application cycle for the Dr. Joel Berley Scholarship for Future Doctors. This prestigious academic grant reflects Dr. Berley’s enduring mission to identify and uplift undergraduate students who are poised to become catalysts for progress in medicine.

PANAMA CITY, July 24, 2025 (GLOBE NEWSWIRE) -- The cryptocurrency market faced heavy volatility as XRP dropped sharply, while LF Labs (LF Coin) attracted attention as a potential safe haven. XRP’s decline followed large wallet transfers, yet LF Labs showed resilience and gained support from a growing investor base. As panic hit XRP, LF Coin’s tokenomics and ecosystem strength helped it stand out during the correction.

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx^® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.